Trial Search Results
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). The phase I portion of this study is being done to find the highest dose of ABT-751 that can be given safely in combination with other chemotherapy drugs. A safe dose is one that does not result in unacceptable side effects. After a safe dose for ABT-751 given with chemotherapy has been found, the study will add additional patients to find out if ABT-751 (given at the maximal safe dose) when given with additional chemotherapy is an effective therapy for the treatment of children with relapsed ALL. It is expected that approximately 15-35 children and young adults will take part in this study.
Stanford is currently not accepting patients for this trial.
Therapeutic Advances in Childhood Leukemia Consortium
- Drug: ABT-751
- Drug: dexamethasone
- Drug: PEG-asparaginase
- Drug: doxorubicin
- Drug: cytarabine
- Drug: methotrexate
- Drug: cyclophosphamide
- Drug: 6-thioguanine
This is an abbreviated list...
- Patients must be less than 21 years of age to be participate in this study.
- Patients must have relapsed acute lymphoblastic leukemia (ALL) without evidence of
central nervous system (CNS) disease.
- Patients must have adequate kidney, heart and liver function.
- Must be able to swallow capsules.
- Patients who are pregnant or breast feeding.
- Patients who have an allergy to Asparaginase products or sulfa-containing medications.
- Patients who have an active uncontrolled infection.
- Patients who have numbness or tingling in the hands or feet or constipation.
Ages Eligible for Study
N/A - 21 Years
Genders Eligible for Study